Trial Profile
Phase II Trial of Definitive Radiotherapy With Leuprolide and Enzalutamide in High Risk Prostate Cancer
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 14 Oct 2021
Price :
$35
*
At a glance
- Drugs Enzalutamide (Primary) ; Leuprorelin (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- 14 Oct 2021 Status changed from completed to discontinued.
- 24 Sep 2020 Status changed from active, no longer recruiting to completed.
- 14 Jul 2020 Planned End Date changed from 1 Jun 2020 to 31 Aug 2020.